SCHEMBL3962465

SCHEMBL3962465

O=COSc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MGLL Q99685 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 7/20 0.36
CYP2A6 P11509 1/20 0.36
MAPK1 P28482 3/20 0.35
FFAR1 O14842 1/20 0.33
LMNA P02545 4/20 0.32
PLIN1 O60240 1/20 0.32
HTT P42858 1/20 0.32
PLIN5 Q00G26 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ABHD5 Q8WTS1 1/20 0.32
KCNH2 Q12809 1/20 0.32
TDP1 Q9NUW8 2/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141775 0.69 HPGD (0.50) HPGDMAPTSMN1; SMN2MGLLHSD17B10
SCHEMBL11312471 0.65 MAOB (0.41) HSD17B10
SCHEMBL4054070 0.65 CYP2D6 (0.38) ALDH1A1CYP2A6MAPK1LMNAKMT2A
SCHEMBL5540734 0.65 ALDH1A1 (0.46) HPGDMAPTSMN1; SMN2MGLLHSD17B10
SCHEMBL1936427 0.65
SCHEMBL5672126 0.65 MAPT (0.45) HPGDMAPTSMN1; SMN2MGLLHSD17B10
SCHEMBL13271640 0.65
SCHEMBL8240702 0.65
SCHEMBL5695276 0.65
SCHEMBL3092615 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009038031-A1 BLOCK COPOLYMER AND PRODUCTION PROCESS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-26 WO disclosed
WO-2009038006-A1 RANDOM COPOLYMER AND PRODUCTION PROCESS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-26 WO disclosed
EP-1657073-B1 Reversible thermochromic composition and microcapsules containing the same PILOT INK CO LTD (JP) 2008-02-27 EP disclosed
US-20070287843-A1 Methods and Intermediates for the Synthesis of Delta-9 Tetrahydrocannabinol CEDARBURG PHARMACEUTICALS, INC. 2007-12-13 US disclosed
EP-1732908-A1 METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF DELTA-9 TETRAHYDROCANNABINOL Cedarburg Pharmaceuticals, Inc. (US) 2006-12-20 EP disclosed
WO-2005100333-A1 METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF DELTA-9 TETRAHYDROCANNABINOL CEDARBURG PHARMACEUTICALS, INC. (US) 2005-10-27 WO disclosed
EP-0188816-B1 NOVEL BETA-LACTAMS AND THEIR PRODUCTION SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1990-10-17 EP disclosed
US-4578485-A Synthesis of spectinomycin analogs by an improved Grignard process THE UPJOHN COMPANY (US) 1986-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287843-A1 Methods and Intermediates for the Synthesis of Delta-9 Tetrahydrocannabinol CNR2, CNR1, CYP8B1 HPGD 231/4885MAPT 816/4885SMN1; SMN2 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.